ORTHOSENSOR® ON THE MAIN AISLE (BOOTH #5823) AT THE 2017 AAOS ANNUAL MEETING IN SAN DIEGO
New VERASENSE™ clinical results, economic savings for revision TKA and our 3-year multicenter study showing 98% patient reported satisfaction for primary TKA will be featured
DANIA BEACH, FL (March 9, 2017) – OrthoSensor, Inc., a leader in sensor-assisted technology for total knee arthroplasty (TKA), will be on the main aisle at booth #5823 during the 2017 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting at the San Diego Convention Center from March 15-17. OrthoSensor will be releasing its three-year multicenter study results, as well as other new studies showing the clinical and economic advantages that may be gained with the use of VERASENSE, the leading intraoperative product for OrthoSensor. OrthoSensor will also host distinguished surgeon speakers at the booth.
VERASENSE for TKA transmits quantitative data from a patient’s knee, enabling a surgeon to customize implant position and achieve better soft tissue balance. The newly released studies show:
- Statistically significant improvement in patient-reported outcomes and satisfaction for TKA patients whose knees were balanced using VERASENSE sensors
- Improved post-op physical therapy performance and short-term clinical outcomes
- Reduced complications and costs over 90-day TKA episode of care (MUA rate)
- Cost mitigation when used for revision TKA (implant preservation, improved rehabilitation and other ancillary benefits)
“We are excited to present a new study showing 88% of planned early stage total revisions changed to partial revisions when VERASENSE was used in revision TKA procedures. This reduction represents very meaningful clinical and financial benefits to both patients and providers. This is just one of many studies showing the significant clinical and economic advantages of VERASENSE that have been recently released,” said Ivan Delevic, President and Chief Executive Officer of OrthoSensor, Inc.
The distinguished presenters at the OrthoSensor Booth #5823 are as follows:
Wednesday, March 15, 2017
10:30 am – Gregory J. Golladay, MD – Virginia Commonwealth University
2:00 pm – Michael Mont, MD – Cleveland Clinic
Thursday, March 16, 2017
10:30 am – Jimmy Chow, MD – St. Luke’s Hospital
2:00 pm – Patrick Meere, MD – NYU Hospital for Joint Diseases
Friday, March 17, 2017
11:00 am – David Fabi, MD – Scripps Mercy Hospital San Diego
ABOUT ORTHOSENSOR, INC.
OrthoSensor, Inc., a leader in Sensor-Assisted Total Knee Arthroplasty develops and commercializes intelligent orthopedic devices and data services that provide quantitative feedback to surgeons and hospitals. The company’s intelligent orthopaedic devices utilize advanced proprietary sensor and communications technologies, coupled with the company’s innovative software products, to facilitate evidence-based decisions in orthopaedic surgery – with the goal of improving patient outcomes and potentially reducing the cost of treating musculoskeletal disease.
OrthoSensor®, VERASENSE™ and ORTHOLOGIQ™ are trademarks of OrthoSensor, Inc.